Why financial and medical decision-making must remain separate in UK fertility Appeared in BioNews 1084 Fertility treatment in the UK – whether accessed via the NHS or privately – has always been considered safe, robust and research-led. It has been regulated for the last 30 years, ensuring that the industry has patients' best interests at heart. But recent weeks have seen a major shift in how private fertility treatment can be paid for, with a major clinic group now offering multi-cycle and refund programmes directly for the first time, removing vital separations between medical and commercial decision-making. I and others believe this could have consequences for patient health.